Loading...
Cart
0
New

Pneumonia Vaccine Market by Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine), by Product Type (Prevnar 13, Synflorix, and Pneumovax 23) and By Sector (Public and Private), by Distribution Channel (Distribution Partner Companies, Non-governmental Organizations and Government Authorities): Opportunity Analysis and Industry Forecast, 2018–2025

LI_182730
Pages: 171
May 2019 | 1733 Views
 
Author(s) : Sagar Mukhekar , Onkar Sumant
Tables: 132
Charts: 24
 

Pneumonia Vaccines Market Outlook - 2025

The global pneumonia vaccines market was valued at $7,083 million in 2017 and is expected to reach $10,215 million by 2025, growing at a CAGR of 5% from 2018 to 2025.

Pneumonia Vaccine Market

Get more information on this report : Request Sample Pages

Pneumonia is a disease that causes lung contamination occurring in one or both the lungs caused by bacterial organisms, viruses, or fungi; bacterial pneumonia is the most common in adults. Pneumonia results in irritation around the ‘sacs’ also known as alveoli of the lungs, which causes the alveoli to fill with pus, as a result causing breathing issues. Pneumococcal diseases are most common in younger children; however, adults and elderly population are more prone to pneumococcal contaminations and even death. Pneumonia vaccines are primarily given to the children less than 2 years and adults 65 years and older. In general, vaccines are given at 2,4,6, and 12 thought 15 months old for children; and single dose will be given for the adults aged 65 years and older. These vaccines help providing immunization against 13 types of pneumococcal bacteria that cause infection in the lungs.

Increasing government support in creating awareness regarding pneumonia immunization programs, rising prevalence of pneumococcal contaminations within the population, and introduction of novel pneumococcal vaccines are some of the major factors driving the growth of the global pneumonia vaccine market. However, longer timelines required for production of pneumococcal vaccines and higher costs associated with development of the vaccines are hindering the growth of the market across the globe. Also, developing the protein-based vaccines for pneumonia are anticipated to create opportunities for the expansion of this market during the forecast period.

Global Pneumonia Vaccine Market Segmentation

The global pneumonia vaccine market is segmented based on vaccine type, product type, sector type, distribution channel and region. Based on vaccine type, the market is divided into Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine. Based on product type, the market is categorized into Prevnar 13, Synflorix, and Pneumovax 23. Based on sector type, the market is divided into Public and Private. Based on distribution channel, the market is segmented into Distribution Partner Companies, Non-governmental Organizations (NGO) and Government Authorities. Based on region, the Global pneumonia vaccine market size is analyzed across North America, Europe, Asia-Pacific and LAMEA.

Pneumonia Vaccine Market by Product

Get more information on this report : Request Sample Pages

Segment review

Based on vaccine type, the market is divided into pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine. The pneumococcal conjugate vaccine segment is largest contributor to the global pneumonia vaccine market in 2017 and is expected to maintain its dominant position throughout the analysis period. These vaccines can immunize the infants and children from 6 weeks to 5 years of age to prevent the invasive disease, pneumonia, and acute otitis media. The PCV vaccines segment is expected to hold the maximum market share owing to rise in adoption and usage of the vaccine amongst the population as many are susceptible to pneumonia, which includes children below 5 years and adults above 50 years. Thus, it contributes the largest share in the global pneumonia vaccines market. On the other side, pneumococcal polysaccharide vaccine segment is the fastest growing segment during the forecast period, owing to the Pneumovax 23 is proven efficacious against invasive pneumonia disease in healthy young adults. It is primarily indicated to use in population aged 50 year and above and population aged more than 2 years.

Pneumonia Vaccine Market by Distribution Channel

Get more information on this report : Request Sample Pages

According to global pneumonia vaccine market analysis, the product type segment is classified into Prevnar 13, Synflorix, and Pneumovax 23. Throughout the forecast period, the Prevnar 13 segment is expected to be the fastest growing segment as it is most widely used pneumonia vaccine across the world; recommended by WHO due to its efficiency in pneumonia prevention. Moreover, Prevnar 13 is also used in adults aged more than 50 years for the prevention of pneumonia disease. Based on sector, the market is divided into two sector namely public and private sectors. The private sector is largest segment contributing to the global pneumonia vaccine market in 2017 and is expected to maintain its dominant position throughout the analysis period. This sector includes private hospitals, clinics, and others. The private hospitals sell vaccines for the treatment of pneumonia at a higher cost as compared to the non-profit organizations. According to global pneumonia vaccine market analysis, the distribution channel segment is segmented into distribution partner companies, non-governmental organizations (NGO) and government authorities. The non-governmental organizations segment is anticipated to be the largest segment due to organizations such as UNICEF, GAVI, charitable trusts, and WHO. They work to improve the healthcare worldwide and provide access of the life-saving medicines to the economically backward population. These organizations purchase pneumonia vaccines from the manufacturer and provide them directly to the destination geographies which predominantly fuels the growth of the global pneumonia vaccine market worldwide.

Pneumonia Vaccine Market by Geography

Get more information on this report : Request Sample Pages

The report provides an extensive competitive analysis and profiles of the key market players such as Glaxosmithkline plc., LG Chem Ltd., Merck & Co., Inc., Panacea Biotec Limited, Pfizer Inc., Pnuvax Incorporated, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd. (Beijing Minhai Biotechnology Corporation Limited), SK Bioscience and Walvax Biotechnology Co., Ltd.

Key Benefits for Pneumonia Vaccines Market:

  • This report entails a detailed quantitative analysis along with the current global pneumonia vaccine market trends of the market from 2017 to 2025 to identify the prevailing opportunities along with the strategic assessment of the Europe market.
  • The global pneumonia vaccine market forecast is studied from 2018 to 2025.
  • The pneumonia vaccine market size and estimations are based on a comprehensive analysis of key developments in the pneumonia vaccine industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the global pneumonia vaccine market.

Pneumonia Vaccines Key Market Segments:

By Vaccine Type

  • Pneumococcal Conjugate Vaccine
  • Pneumococcal Polysaccharide Vaccine

By Product Type

  • Prevnar 13
  • Synflorix
  • Pneumovax 23

By Sector

  • Public
  • Private

By distribution channel

  • Distribution Partner Companies
  • Non-governmental Organizations (NGO)
  • Government Authorities

By Region

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA
 

CHAPTER 1:    INTRODUCTION

1.1.    Report description
1.2.    Key benefits for stakeholders
1.3.    Key market segments
1.4.    Research methodology

1.4.1.    Secondary research
1.4.2.    Primary research
1.4.3.    Analyst tools and models

CHAPTER 2:    EXECUTIVE SUMMARY

2.1.    Key findings of the study
2.2.    CXO perspective

CHAPTER 3:    MARKET OVERVIEW

3.1.    Market definition and scope
3.2.    Key findings

3.2.1.    Top investment pockets
3.2.2.    Top winning strategies, 2016–2018
3.2.3.    Top strategies:

3.3.    Porters five forces analysis

3.3.1.    Bargaining power of suppliers
3.3.2.    Threat of new entrants
3.3.3.    Threat of substitutes
3.3.4.    Competitive rivalry
3.3.5.    Bargaining power among buyers

3.4.    Market share analysis, 2018
3.5.    Market dynamics

3.5.1.    Drivers

3.5.1.1.    Surge in prevalence of pneumonia across the globe
3.5.1.2.    Rise in government focus on immunization programs for pneumonia
3.5.1.3.    Increase in focus for novel pneumococcal vaccines

3.5.2.    Restraints

3.5.2.1.    Longer timelines required for pneumonia vaccine production
3.5.2.2.    High cost associated with development of such vaccines

3.5.3.    Opportunity

3.5.3.1.    Development of protein-based combination pneumococcal vaccines

CHAPTER 4:    PNEUMONIA VACCINES MARKET, BY VACCINE TYPE

4.1.    Overview

4.1.1.    Market size and forecast

4.2.    Pneumococcal conjugate vaccine (PCV)

4.2.1.    Key market trends, growth factors and opportunities
4.2.2.    Market size and forecast

4.3.    Pneumococcal polysaccharide vaccine (PPSV/PPV)

4.3.1.    Key market trends, growth factors and opportunities
4.3.2.    Market size and forecast

CHAPTER 5:    PNEUMONIA VACCINES MARKET, BY PRODUCT TYPE

5.1.    Overview

5.1.1.    Market size and forecast

5.2.    Prevnar 13

5.2.1.    Key market trends, growth factors and opportunities
5.2.2.    Market size and forecast

5.3.    Synflorix

5.3.1.    Key market trends, growth factors and opportunities
5.3.2.    Market size and forecast

5.4.    Pneumovax23

5.4.1.    Key market trends, growth factors and opportunities
5.4.2.    Market size and forecast

5.5.    Pipeline Products

CHAPTER 6:    PNEUMONIA VACCINES MARKET, BY SECTOR

6.1.    Overview

6.1.1.    Market size and forecast

6.2.    Public sector

6.2.1.    Market size and forecast

6.3.    Private sector

6.3.1.    Market size and forecast

CHAPTER 7:    PNEUMONIA VACCINES MARKET, BY DISTRIBUTION CHANNEL

7.1.    Overview

7.1.1.    Market size and forecast

7.2.    Distribution partner companies

7.2.1.    Key market trends, growth factors and opportunities
7.2.2.    Market size and forecast

7.3.    Non-governmental Organizations (NGO)

7.3.1.    Key market trends, growth factors and opportunities
7.3.2.    Market size and forecast

7.4.    Government Authorities

7.4.1.    Key market trends, growth factors and opportunities
7.4.2.    Market size and forecast

CHAPTER 8:    GLOBAL PNEUMONIA MARKET, BY REGION

8.1.    Overview

8.1.1.    Market size and forecast

8.2.    North America

8.2.1.    Key market trends
8.2.2.    Key growth factors and opportunities
8.2.3.    Market size and forecast, by type
8.2.4.    Market size and forecast, by product type
8.2.5.    Market size and forecast, by distribution channel
8.2.6.    Market size and forecast, by sector
8.2.7.    Market size and forecast, by country

8.2.7.1.    The U.S. Pneumonia Vaccine Market

8.2.7.1.1.    Market Size and forecast, by type
8.2.7.1.2.    Market Size and forecast, by product type
8.2.7.1.3.    Market Size and forecast, by distribution channel
8.2.7.1.4.    Market Size and forecast, by sector

8.2.7.2.    Canada Pneumonia Vaccine Market

8.2.7.2.1.    Market Size and forecast, by type
8.2.7.2.2.    Market Size and forecast, by product type
8.2.7.2.3.    Market Size and forecast, by distribution channel
8.2.7.2.4.    Market Size and forecast, by sector

8.2.7.3.    Mexico Pneumonia Vaccine Market

8.2.7.3.1.    Market Size and forecast, by type
8.2.7.3.2.    Market Size and forecast, by product type
8.2.7.3.3.    Market Size and forecast, by distribution channel
8.2.7.3.4.    Market Size and forecast, by sector

8.3.    Europe

8.3.1.    Key market trends
8.3.2.    Key growth factors and opportunities
8.3.3.    Market size and forecast, by type
8.3.4.    Market size and forecast, by product type
8.3.5.    Market size and forecast, by distribution channel
8.3.6.    Market size and forecast, by sector
8.3.7.    Market size and forecast, by country

8.3.7.1.    Germany Pneumonia Vaccine Market

8.3.7.1.1.    Market Size and forecast, by type
8.3.7.1.2.    Market Size and forecast, by product type
8.3.7.1.3.    Market Size and forecast, by distribution channel
8.3.7.1.4.    Market Size and forecast, by sector

8.3.7.2.    France Pneumonia Vaccine Market

8.3.7.2.1.    Market Size and forecast, by type
8.3.7.2.2.    Market Size and forecast, by product type
8.3.7.2.3.    Market Size and forecast, by distribution channel
8.3.7.2.4.    Market Size and forecast, by sector

8.3.7.3.    UK Pneumonia Vaccine Market

8.3.7.3.1.    Market Size and forecast, by type
8.3.7.3.2.    Market Size and forecast, by product type
8.3.7.3.3.    Market Size and forecast, by distribution channel
8.3.7.3.4.    Market Size and forecast, by sector

8.3.7.4.    Spain Pneumonia Vaccine Market

8.3.7.4.1.    Market Size and forecast, by type
8.3.7.4.2.    Market Size and forecast, by product type
8.3.7.4.3.    Market Size and forecast, by distribution channel
8.3.7.4.4.    Market Size and forecast, by sector

8.3.7.5.    Italy Pneumonia Vaccine Market

8.3.7.5.1.    Market Size and forecast, by type
8.3.7.5.2.    Market Size and forecast, by product type
8.3.7.5.3.    Market Size and forecast, by distribution channel
8.3.7.5.4.    Market Size and forecast, by sector

8.3.7.6.    Rest of Europe Pneumonia Vaccine Market

8.3.7.6.1.    Market Size and forecast, by type
8.3.7.6.2.    Market Size and forecast, by product type
8.3.7.6.3.    Market Size and forecast, by distribution channel
8.3.7.6.4.    Market Size and forecast, by sector

8.4.    Asia-Pacific

8.4.1.    Key market trends
8.4.2.    Key growth factors and opportunities
8.4.3.    Market size and forecast, by type
8.4.4.    Market size and forecast, by product type
8.4.5.    Market size and forecast, by distribution channel
8.4.6.    Market size and forecast, by sector
8.4.7.    Market size and forecast, by country

8.4.7.1.    Japan Pneumonia Vaccine Market

8.4.7.1.1.    Market Size and forecast, by type
8.4.7.1.2.    Market Size and forecast, by product type
8.4.7.1.3.    Market Size and forecast, by distribution channel
8.4.7.1.4.    Market Size and forecast, by sector

8.4.7.2.    China Pneumonia Vaccine Market

8.4.7.2.1.    Market Size and forecast, by type
8.4.7.2.2.    Market Size and forecast, by product type
8.4.7.2.3.    Market Size and forecast, by distribution channel
8.4.7.2.4.    Market Size and forecast, by sector

8.4.7.3.    India Pneumonia Vaccine Market

8.4.7.3.1.    Market Size and forecast, by type
8.4.7.3.2.    Market Size and forecast, by product type
8.4.7.3.3.    Market Size and forecast, by distribution channel
8.4.7.3.4.    Market Size and forecast, by sector

8.4.7.4.    Rest of Asia-Pacific Pneumonia Vaccine Market

8.4.7.4.1.    Market Size and forecast, by type
8.4.7.4.2.    Market Size and forecast, by product type
8.4.7.4.3.    Market Size and forecast, by distribution channel
8.4.7.4.4.    Market Size and forecast, by sector

8.5.    LAMEA

8.5.1.    Key market trends
8.5.2.    Key growth factors and opportunities
8.5.3.    Market size and forecast, by type
8.5.4.    Market size and forecast, by product type
8.5.5.    Market size and forecast, by distribution channel
8.5.6.    Market size and forecast, by sector
8.5.7.    Market size and forecast, by country

8.5.7.1.    Brazil Pneumonia Vaccine Market

8.5.7.1.1.    Market Size and forecast, by type
8.5.7.1.2.    Market Size and forecast, by product type
8.5.7.1.3.    Market Size and forecast, by distribution channel
8.5.7.1.4.    Market Size and forecast, by sector

8.5.7.2.    South Africa Pneumonia Vaccine Market

8.5.7.2.1.    Market Size and forecast, by type
8.5.7.2.2.    Market Size and forecast, by product type
8.5.7.2.3.    Market Size and forecast, by distribution channel
8.5.7.2.4.    Market Size and forecast, by sector

8.5.7.3.    Saudi Arabia Pneumonia Vaccine Market

8.5.7.3.1.    Market Size and forecast, by type
8.5.7.3.2.    Market Size and forecast, by product type
8.5.7.3.3.    Market Size and forecast, by distribution channel
8.5.7.3.4.    Market Size and forecast, by sector

8.5.7.4.    Rest of LAMEA Pneumonia Vaccine Market

8.5.7.4.1.    Market Size and forecast, by type
8.5.7.4.2.    Market Size and forecast, by product type
8.5.7.4.3.    Market Size and forecast, by distribution channel
8.5.7.4.4.    Market Size and forecast, by sector

CHAPTER 9:    COMPANY PROFILES

9.1.    GLAXOSMITHKLINE PLC.

9.1.1.    Company overview
9.1.2.    Company snapshot
9.1.3.    Operating business segments
9.1.4.    Product Portfolio
9.1.5.    Business performance

9.2.    LG CHEM LTD.

9.2.1.    Company overview
9.2.2.    Company snapshot
9.2.3.    Operating business segments
9.2.4.    Product portfolio
9.2.5.    Business performance

9.3.    MERCK & CO., INC.

9.3.1.    Company overview
9.3.2.    Company snapshot
9.3.3.    Operating business segments
9.3.4.    Product Portfolio
9.3.5.    Business performance

9.4.    PANACEA BIOTEC LIMITED

9.4.1.    Company overview
9.4.2.    Company snapshot
9.4.3.    Operating business segments
9.4.4.    Product portfolio

9.4.5.    Business performance

9.5.    PFIZER INC.

9.5.1.    Company overview
9.5.2.    Company snapshot
9.5.3.    Operating business segments
9.5.4.    Product portfolio
9.5.5.    Business performance

9.6.    PNUVAX INCORPORATED

9.6.1.    Company overview
9.6.2.    Company snapshot
9.6.3.    Product portfolio

9.7.    SERUM INSTITUTE OF INDIA PVT. LTD.

9.7.1.    Company overview
9.7.2.    Company snapshot
9.7.3.    Product portfolio

9.8.    SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. (BEIJING MINHAI BIOTECHNOLOGY CORPORATION LIMITED)

9.8.1.    Company overview
9.8.2.    Company snapshot
9.8.3.    Product portfolio

9.9.    SK BIOSCIENCE

9.9.1.    Company overview
9.9.2.    Company snapshot
9.9.3.    Product portfolio

9.10.    WALVAX BIOTECHNOLOGY CO., LTD.

9.10.1.    Company overview
9.10.2.    Company snapshot
9.10.3.    Product Portfolio

LIST OF TABLES

TABLE 01.    PNEUMONIA VACCINES MARKET, BY VACCINE TYPE, 2017–2025 ($MILLION)
TABLE 02.    PNEUMONIA VACCINES MARKET FOR PNEUMOCOCCAL CONJUGATE VACCINES, BY REGION, 2017–2025 ($MILLION)
TABLE 03.    PNEUMONIA VACCINES MARKET FOR PNEUMOCOCCAL POLYSACCHARIDE VACCINES, BY REGION, 2017–2025 ($MILLION)
TABLE 04.    PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 05.    PNEUMONIA VACCINE MARKET FOR PREVNAR 13, BY REGION, 2017–2025 ($MILLION)
TABLE 06.    PNEUMONIA VACCINE MARKET FOR PREVNAR 13, BY TARGET POPULATION, 2017–2025 ($MILLION)
TABLE 07.    PNEUMONIA VACCINE MARKET FOR SYNFLORIX, BY REGION, 2017–2025 ($MILLION)
TABLE 08.    PNEUMONIA VACCINE MARKET FOR SYNFLORIX, BY TARGET POPULATION, 2017–2025 ($MILLION)
TABLE 09.    PNEUMONIA VACCINE MARKET FOR PNEUMOVAX23, BY REGION, 2017–2025 ($MILLION)
TABLE 10.    PNEUMONIA VACCINE MARKET FOR PNEUMOVAX, BY TARGET POPULATION, 2017–2025 ($MILLION)
TABLE 11.    PNEUMONIA VACCINE PRODUCT PIPELINE
TABLE 12.    PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 13.    PNEUMONIA VACCINE MARKET BY PUBLIC SECTOR, 2017–2025 ($MILLION)
TABLE 14.    PNEUMONIA VACCINE MARKET, BY PRIVATE SECTOR, 2017–2025 ($MILLION)
TABLE 15.    PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 16.    PNEUMONIA VACCINE MARKET FOR DISTRIBUTION PARTNER COMPANIES, BY REGION, 2017–2025 ($MILLION)
TABLE 17.    PNEUMONIA VACCINE MARKET FOR NON-GOVERNMENTAL ORGANIZATIONS, BY REGION, 2017–2025 ($MILLION)
TABLE 18.    PNEUMONIA VACCINE MARKET FOR GOVERNMENT AUTHORITIES, BY REGION, 2017–2025 ($MILLION)
TABLE 19.    PNEUMONIA VACCINE MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 20.    NORTH AMERICA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 21.    NORTH AMERICA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 22.    NORTH AMERICAPNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 23.    NORTH AMERICAPNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 24.    NORTH AMERICA PNEUMONIA VACCINE MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 25.    THE U.S. PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 26.    THE U.S. PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 27.    THE U.S. PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 28.    THE U.S. PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 29.    CANADA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 30.    CANADA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 31.    CANADA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 32.    CANADA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 33.    MEXICO PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 34.    MEXICO PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 35.    MEXICO PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 36.    MEXICO PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 37.    EUROPE PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 38.    EUROPE PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 39.    EUROPE PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 40.    EUROPE PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 41.    EUROPE PNEUMONIA VACCINE MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 42.    GERMANY PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 43.    GERMANY PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 44.    GERMANY PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 45.    GERMANY PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 46.    FRANCE PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 47.    FRANCE PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 48.    FRANCE PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 49.    FRANCE PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 50.    UK PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 51.    UK PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 52.    UK PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 53.    UK PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 54.    SPAIN PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 55.    SPAIN PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 56.    SPAIN PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 57.    SPAIN PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 58.    ITALY PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 59.    ITALY PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 60.    ITALY PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 61.    ITALY PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 62.    REST OF EUROPE PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 63.    REST OF EUROPE PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 64.    REST OF EUROPE PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 65.    REST OF EUROPE PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 66.    ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 67.    ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 68.    ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 69.    ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 70.    ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 71.    JAPAN PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 72.    JAPAN PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 73.    JAPAN PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 74.    JAPAN PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 75.    CHINA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 76.    CHINA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 77.    CHINA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 78.    CHINA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 79.    INDIA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 80.    INDIA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 81.    INDIA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 82.    INDIA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 83.    REST OF ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 84.    REST OF ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 85.    REST OF ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 86.    REST OF ASIA-PACIFIC PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 87.    LAMEA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 88.    LAMEA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 89.    LAMEA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 90.    LAMEA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 91.    LAMEA PNEUMONIA VACCINE MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 92.    BRAZIL PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 93.    BRAZIL PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 94.    BRAZIL PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 95.    BRAZIL PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 96.    SOUTH AFRICA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 97.    SOUTH AFRICA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 98.    SOUTH AFRICA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 99.    SOUTH AFRICA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 100.    SAUDI ARABIA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 101.    SAUDI ARABIA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 102.    SAUDI ARABIA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 103.    SAUDI ARABIA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 104.    REST OF LAMEA PNEUMONIA VACCINE MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 105.    REST OF LAMEA PNEUMONIA VACCINE MARKET, BY PRODUCT TYPE, 2017–2025 ($MILLION)
TABLE 106.    REST OF LAMEA PNEUMONIA VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 107.    REST OF LAMEA PNEUMONIA VACCINE MARKET, BY SECTOR, 2017–2025 ($MILLION)
TABLE 108.    GSK: COMPANY SNAPSHOT
TABLE 109.    GSK: OPERATING SEGMENTS
TABLE 110.    GSK: PRODUCT PORTFOLIO
TABLE 111.    LG CHEM: COMPANY SNAPSHOT
TABLE 112.    LG CHEM: OPERATING SEGMENTS
TABLE 113.    KINDER MORGAN: PRODUCT PORTFOLIO
TABLE 114.    MERCK: COMPANY SNAPSHOT
TABLE 115.    MERCK: OPERATING SEGMENTS
TABLE 116.    MERCK: PRODUCT PORTFOLIO
TABLE 117.    PANACEA BIOTEC: COMPANY SNAPSHOT
TABLE 118.    PANACEA BIOTEC: OPERATING SEGMENTS
TABLE 119.    PANACEA BIOTEC: PRODUCT PORTFOLIO
TABLE 120.    PFIZER: COMPANY SNAPSHOT
TABLE 121.    PFIZER: OPERATING SEGMENTS
TABLE 122.    PFIZER: PRODUCT PORTFOLIO
TABLE 123.    PNUVAX: COMPANY SNAPSHOT
TABLE 124.    PNUVAX: PRODUCT PORTFOLIO
TABLE 125.    SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY SNAPSHOT
TABLE 126.    SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT PORTFOLIO
TABLE 127.    SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.: COMPANY SNAPSHOT
TABLE 128.    SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.: PRODUCT PORTFOLIO
TABLE 129.    SK BIOSCIENCE: COMPANY SNAPSHOT
TABLE 130.    SK BIOSCIENCE: PRODUCT PORTFOLIO
TABLE 131.    WALVAX: COMPANY SNAPSHOT
TABLE 132.    WALVAX: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.    PNEUMONIA VACCINES MARKET SEGMENTATION
FIGURE 02.    TOP INVESTMENT POCKETS
FIGURE 03.    BARGAINING POWER OF SUPPLIERS
FIGURE 04.    THREAT OF NEW ENTRANTS
FIGURE 05.    THREAT OF SUBSTITUTES
FIGURE 06.    COMPETITIVE RIVALRY
FIGURE 07.    BARGAINING POWER AMONG BUYERS
FIGURE 08.    MARKET SHARE ANALYSIS, 2018
FIGURE 09.    IMPACT ANALYSIS
FIGURE 10.    GSK: REVENUE, 2016–2018 ($MILLION)
FIGURE 11.    GSK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 12.    GSK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 13.    LG CHEM: NET SALES, 2015–2017 ($MILLION)
FIGURE 14.    LG CHEM: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 15.    LG CHEM: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 16.    MERCK: NET SALES, 2016–2018 ($MILLION)
FIGURE 17.    MERCK: NET SALES BY SEGMENT, 2018 (%)
FIGURE 18.    MERCK: NET SALES BY REGION, 2018 (%)
FIGURE 19.    PANACEA BIOTEC: NET SALES, 2016–2018 ($MILLION)
FIGURE 20.    PANACEA BIOTEC: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 21.    PANACEA BIOTEC: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 22.    PFIZER: NET SALES, 2016–2018 ($MILLION)
FIGURE 23.    PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 24.    PFIZER: REVENUE SHARE BY REGION, 2018 (%)

 
 

Adoption of pneumonia vaccines has witnessed significant growth due to the focus of government bodies and precautionary measures undertaken by the healthcare organizations to reduce the death rates caused by pneumonia bacteria. Moreover, rise in prevalence of pneumonia within the developing countries further boosts the demand of the pneumonia vaccines market. The pneumonia vaccines market has gained interest of non-government organizations such as Global Action Plan for the Prevention and Control of Pneumonia and Diarrhea (GAPPD) and Gates Foundation to reduce the deaths caused by pneumococcal bacteria as these vaccines provide complete immunization against the disease. NGOs are encouraging the manufacturers to develop novel pneumonia vaccines to cater to the large demand for pneumonia immunizations. In addition, increase in number of childbirth rates and surge in geriatric population are some of the factors that further drive the market growth.

In addition, North America is expected to dominate the growth of the global pneumonia vaccines market during the forecast period, followed by Europe. This is attributed to the presence of sophisticated healthcare infrastructure and surge in geriatric population susceptible to pneumonia. Moreover, Asia-Pacific is expected to offer lucrative opportunities for the market players during the forecast period.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Download Sample

Request Customization

 

Download Sample

OR

Purchase Full Report of
Pneumonia Vaccine Market

  • Online Only
  • $3456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3840
  • Restricted to one authorized user
  • One print only
  • Available in Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5370
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8995
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 
Download Sample

Buy Full Version
"Pneumonia Vaccine Market"
Purchase Enquiry